Senescent IECs orchestrate a bile acid–mediated brake on stem cell hyperproliferation via SASP‑driven glucocorticoid receptor antagonism

Hypothesis

Age‑related accumulation of senescent intestinal epithelial cells (IECs) actively suppresses the apical sodium‑dependent bile acid transporter (ASBT) through SASP‑mediated interference with glucocorticoid receptor (GR) signaling. This repression lowers bile acid reabsorption, elevates luminal bile acids, and activates TGR5‑dependent signaling that restrains intestinal epithelial stem cell (IESC) proliferation. Senolytic clearance of senescent IECs would therefore restore ASBT, decrease luminal bile acids, blunt TGR5 signaling, and unleash IESC hyperproliferation—a trade‑off where removing the "hostage negotiator" removes a protective brake on tissue growth.

Mechanistic Model

• Senescent IECs secrete IL‑6, TNFα, and IL‑1β (core SASP).
• These cytokines activate STAT3 and NF‑κB pathways in neighboring IECs, leading to upregulation of SIRT1 and increased expression of miR‑21.
• SIRT1 deacetylates GR, reducing its ligand‑dependent transcriptional activity; miR‑21 directly targets GR mRNA for degradation.
• Impaired GR signaling diminishes transcription of the ASBT gene (SLC10A2) despite normal receptor levels.
• Reduced ASBT activity lowers ileal bile acid uptake, increasing luminal concentrations of secondary bile acids (e.g., deoxycholic acid).
• Elevated luminal bile acids activate TGR5 on enteroendocrine cells, stimulating GLP‑1 and PYY release, which act paracrinely to inhibit IESC proliferation via cAMP‑PKA signaling.
• Thus, senescence creates a feedback loop: SASP → GR inhibition → ↓ASBT → ↑luminal bile acids → ↑TGR5 signaling → ↓IESC proliferation.

Testable Predictions

1. In aged mice, senolytic treatment (e.g., dasatinib + quercetin) will increase ASBT mRNA and protein in ileal epithelium.
2. Concomitant with ASBT up‑regulation, ileal bile acid content will fall and fecal bile acid excretion will rise.
3. TGR5 target gene expression (e.g., cAMP‑responsive element‑binding protein phosphorylation) will decrease after senolysis.
4. IESC proliferation markers (Ki67, phospho‑histone H3) will rise in senolytic‑treated aged mice compared with age‑matched controls.
5. In a carcinogen‑induced colitis‑associated cancer model, senolysis will exacerbate tumor burden, which can be rescued by pharmacological TGR5 activation or by bile acid sequestration.

Experimental Approach

• Animal groups: young (3 mo), aged (18 mo) untreated, aged + senolytic (dasatinib 5 mg/kg + quercetin 50 mg/kg, twice weekly for 4 weeks), aged + senolytic + TGR5 agonist (intra‑ileal).
• Readouts: qPCR/Western blot for ASBT and GR; immunofluorescence for senescent marker p16^INK4a^; bile acid quantification by LC‑MS; TGR5 signaling via pCREB staining; IESC proliferation via Ki67 and EdU incorporation; tumor counting and histology after AOM/DSS treatment.
• Statistical analysis: ANOVA with post‑hoc Tukey test; power analysis to detect 20 % changes with n = 8 per group.

If the predictions hold, the data will support the concept that senescent IECs act as a bile acid‑mediated checkpoint that limits stem cell-driven hyperplasia. Failure to observe the expected shifts would falsify the hypothesis and suggest alternative roles for senescence in intestinal aging.